Novo said Tuesday that CagriSema, a semaglutide and cagrilintide injection expected early next year, averaged 25% weight loss at 68 weeks in a post-trial analysis of roughly 2,300 women with obesity or overweight versus 3% on placebo; in about 1,900 women by menopausal status, loss reached 26.7%, 24